For research use only. Not for therapeutic Use.
Prulifloxacin（Cat No.:I000929）is a broad-spectrum fluoroquinolone antibiotic and a prodrug of ulifloxacin, designed to treat various bacterial infections, including respiratory, urinary, and gastrointestinal infections. Upon administration, prulifloxacin is converted to its active form, ulifloxacin, which inhibits bacterial DNA gyrase and topoisomerase IV, enzymes crucial for DNA replication and repair, resulting in bacterial cell death. Known for its good oral bioavailability and tissue penetration, prulifloxacin is effective against both Gram-positive and Gram-negative bacteria. Its safety profile and efficacy make it useful in managing community-acquired and hospital-acquired infections.
| Catalog Number | I000929 |
| CAS Number | 123447-62-1 |
| Molecular Formula | C21H20FN3O6S |
| Purity | ≥95% |
| Target | Bacterial |
| Solubility | DMSO: ＞ 19.5 mg/mL |
| Storage | Store at -20C |
| IUPAC Name | 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid |
| InChI | InChI=1S/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28) |
| InChIKey | PWNMXPDKBYZCOO-UHFFFAOYSA-N |
| SMILES | CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C |
| Reference | </br>1:Prulifloxacin vs Levofloxacin for Exacerbation of COPD after Failure of Other Antibiotics. Giusti M, Blasi F, Iori I, Mazzone A, Sgambato F, Politi C, Colagrande P, Casali A, Valerio A, Gussoni G, Bonizzoni E, Campanini M.COPD. 2016 Oct;13(5):555-60. doi: 10.3109/15412555.2016.1152236. Epub 2016 Mar 30. PMID: 27027547 </br>2:Role of prulifloxacin in the treatment of acute rhinosinusitis. Passali D, Crisanti A, Bellussi LM.Infez Med. 2015 Dec;23(4):301-6. PMID: 26700078 Free Article</br>3:Stability study of Prulifloxacin and Ulifloxacin in human plasma by HPLC-DAD. Locatelli M, Cifelli R, Carlucci G, Romagnoli A.J Enzyme Inhib Med Chem. 2016;31(1):106-11. doi: 10.3109/14756366.2015.1004062. Epub 2015 Feb 16. PMID: 25683081 </br>4:Chronic bacterial prostatitis: efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®). Busetto GM, Giovannone R, Ferro M, Tricarico S, Del Giudice F, Matei DV, De Cobelli O, Gentile V, De Berardinis E.BMC Urol. 2014 Jul 19;14:53. doi: 10.1186/1471-2490-14-53. PMID: 25038794 Free PMC Article</br>5:Prulifloxacin vs fosfomycin for prophylaxis in female patients with recurrent UTIs: a non-inferiority trial. Costantini E, Zucchi A, Salvini E, Cicalese A, Li Marzi V, Filocamo MT, Bini V, Lazzeri M.Int Urogynecol J. 2014 Sep;25(9):1173-8. doi: 10.1007/s00192-013-2318-1. Epub 2014 Feb 20. PMID: 24554302 </br>6:Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece. Karageorgopoulos DE, Maraki S, Vatopoulos AC, Samonis G, Schito GC, Falagas ME.Eur J Clin Microbiol Infect Dis. 2013 Nov;32(11):1417-22. doi: 10.1007/s10096-013-1891-z. Epub 2013 May 19. PMID: 23686506 </br>7:Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis. Blasi F, Schaberg T, Centanni S, Del Vecchio A, Rosignoli MT, Dionisio P.Pulm Pharmacol Ther. 2013 Oct;26(5):609-16. doi: 10.1016/j.pupt.2013.03.014. Epub 2013 Mar 26. PMID: 23538168 </br>8:High performance liquid chromatography determination of prulifloxacin and five related impurities in pharmaceutical formulations. Locatelli M, De Lutiis F, Carlucci G.J Pharm Biomed Anal. 2013 May 5;78-79:27-33. doi: 10.1016/j.jpba.2013.01.036. Epub 2013 Feb 4. PMID: 23434526 </br>9:Sensitive determination of DNA based on the interaction between prulifloxacin-terbium(III) complex and DNA. Wu T, Fang B, Chang L, Liu M, Chen F.Luminescence. 2013 Nov-Dec;28(6):894-9. doi: 10.1002/bio.2453. Epub 2013 Jan 7. PMID: 23297144 </br>10:Development and Validation of a RP-HPLC Method for Estimation of Prulifloxacin in Tablet Dosage Form. Singh S, Singh UK, Singh RM, Singh GN, Mathur SC, Saini PK, Yadav A, Gupta V, Duggal D.Indian J Pharm Sci. 2011 Sep;73(5):577-9. doi: 10.4103/0250-474X.99019. PMID: 22923873 Free PMC Article |
